{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T23:52:53Z","timestamp":1791417173192,"version":"4.3.3"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.semarthrit.2026.153082","type":"journal-article","created":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T15:08:54Z","timestamp":1789830534000},"page":"153082","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Comparative efficacy and safety of disease-modifying antirheumatic drugs tapering strategies in sustained-remission rheumatoid arthritis: Systematic review and network meta-analysis"],"prefix":"10.1016","volume":"81","author":[{"given":"Yosi Yohanes Putra","family":"Tandi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Yasir","family":"Syafa'atulloh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yitzchak Millenard","family":"Sigilipu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Garuda Nusantara Putra","family":"Utomo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Abdir Rahman","family":"Albarok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen Hilkia","family":"Pramatya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laniyati","family":"Hamijoyo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.semarthrit.2026.153082_bib0042","first-page":"s50","article-title":"Rheumatoid arthritis: from palliation to remission in two decades","volume":"14 Suppl 6","author":"PM","year":"2014","journal-title":"Clin Med (Lond)"},{"key":"10.1016\/j.semarthrit.2026.153082_bib0043","doi-asserted-by":"crossref","unstructured":"Messelink, MA, den Broeder, AA, Marinelli, FE, Michgels, E, Verschueren, P, Aletaha, D, Tekstra, J, Welsing, PMJ, What is the best target in a treat-to-target strategy in rheumatoid arthritis? Results from a systematic review and meta-regression analysis., RMD Open, 2023, 9.","DOI":"10.1136\/rmdopen-2023-003196"},{"issue":"1","key":"10.1016\/j.semarthrit.2026.153082_bib0044","doi-asserted-by":"crossref","first-page":"102018","DOI":"10.1016\/j.berh.2024.102018","article-title":"Theory & practice of Treat-to-Target (T2T) in rheumatoid arthritis","volume":"39","author":"J","year":"2025","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"1","key":"10.1016\/j.semarthrit.2026.153082_bib0045","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1136\/ard-2022-223356","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update","volume":"82","author":"JS","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.semarthrit.2026.153082_bib0046","doi-asserted-by":"crossref","first-page":"140","DOI":"10.15586\/aei.v53i3.1278","article-title":"The efficacy and safety of biologic or targeted synthetic DMARDs in rheumatoid arthritis treatment: one year of review 2024","volume":"53","author":"D","year":"2025","journal-title":"Allergol Immunopathol (Madr)"},{"key":"10.1016\/j.semarthrit.2026.153082_bib0047","unstructured":"Nimmana, BK, Patel, P, Disease-Modifying Antirheumatic Drugs (DMARDs)., 2025, Treasure Island (FL), StatPearls Publishing."},{"issue":"7","key":"10.1016\/j.semarthrit.2026.153082_bib0048","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1002\/acr.24596","article-title":"2021 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis","volume":"73","author":"L","year":"2021","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"9","key":"10.1016\/j.semarthrit.2026.153082_bib0049","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1136\/annrheumdis-2020-217485","article-title":"Tapering towards DMARD-free remission in established rheumatoid arthritis: 2-year results of the TARA trial","volume":"79","author":"E","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"9870","key":"10.1016\/j.semarthrit.2026.153082_bib0023","first-page":"29","article-title":"Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial","volume":"381","author":"JS","year":"2013","journal-title":"Lancet"},{"issue":"apr09 23","key":"10.1016\/j.semarthrit.2026.153082_bib0024","doi-asserted-by":"crossref","first-page":"h1389","DOI":"10.1136\/bmj.h1389","article-title":"Disease activity guided dose reduction and withdrawal of adalimumab or etanercept compared with usual care in rheumatoid arthritis: open label, randomised controlled, non-inferiority trial","volume":"350","author":"van Herwaarden","year":"2015","journal-title":"BMJ"},{"issue":"17","key":"10.1016\/j.semarthrit.2026.153082_bib0033","doi-asserted-by":"crossref","first-page":"1755","DOI":"10.1001\/jama.2021.4542","article-title":"Effect of Half-Dose vs Stable-Dose Conventional Synthetic Disease-Modifying Antirheumatic Drugs on Disease Flares in Patients With Rheumatoid Arthritis in Remission","volume":"325","author":"Lillegraven","year":"2021","journal-title":"JAMA"},{"issue":"11","key":"10.1016\/j.semarthrit.2026.153082_bib0034","doi-asserted-by":"crossref","first-page":"e767","DOI":"10.1016\/S2665-9913(21)00220-4","article-title":"Treatment tapering and stopping in patients with rheumatoid arthritis in stable remission (RETRO): a multicentre, randomised, controlled, open-label, phase 3 trial","volume":"3","author":"Tascilar","year":"2021","journal-title":"The Lancet Rheumatology"},{"issue":"6","key":"10.1016\/j.semarthrit.2026.153082_bib0035","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1080\/03009742.2021.1955467","article-title":"Tapering of Etanercept is feasible in patients with Rheumatoid Arthritis in sustained remission: a pragmatic randomized controlled trial","volume":"51","author":"Bertrand","year":"2021","journal-title":"Scandinavian Journal of Rheumatology"},{"issue":"2","key":"10.1016\/j.semarthrit.2026.153082_bib0036","doi-asserted-by":"crossref","first-page":"e002796","DOI":"10.1136\/rmdopen-2022-002796","article-title":"Flare during tapering of biological DMARDs in patients with rheumatoid arthritis in routine care: characteristics and predictors","volume":"8","author":"Terslev","year":"2022","journal-title":"RMD Open"},{"issue":"4","key":"10.1016\/j.semarthrit.2026.153082_bib0037","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1111\/1756-185X.14616","article-title":"Paradigm guiding to tapering or discontinuation of biologic and targeted synthetic disease\u2010modifying antirheumatic drugs in the treatment of patients with rheumatoid arthritis: Results from a local prospective study","volume":"26","author":"Kaban","year":"2023","journal-title":"International Journal of Rheumatic Diseases"},{"key":"10.1016\/j.semarthrit.2026.153082_bib0038","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1136\/annrheumdis-2024-eular.5267","article-title":"POS0600\u2005DOSE REDUCTION STRATEGY OF BIOLOGIC DRUGS IN RA PATIENTS IN REMISSION: A MODEL TO PREDICTIVE FLARE","volume":"83","author":"Blanco","year":"2024","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"1","key":"10.1016\/j.semarthrit.2026.153082_bib0039","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-025-03672-y","article-title":"Stepwise dose reduction and discontinuation of bDMARD in rheumatoid arthritis: a prospective cohort study of flare-free population, flares, and predictive markers","volume":"27","author":"Nozaki","year":"2025","journal-title":"Arthritis Research & Therapy"},{"key":"10.1016\/j.semarthrit.2026.153082_bib0040","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.ard.2025.05.820","article-title":"POS0434\u2005IS METHOTREXATE TAPERING POSSIBLE IN STABLE RA CLINICAL OBSERVATIONS OF METHOTREXATE TAPERING AT TWO TERTIARY CARE CENTERS","volume":"84","author":"Sharma","year":"2025","journal-title":"Annals of the Rheumatic Diseases"},{"key":"10.1016\/j.semarthrit.2026.153082_bib0041","doi-asserted-by":"crossref","first-page":"152831","DOI":"10.1016\/j.semarthrit.2025.152831","article-title":"Discontinuation versus continuation of maintenance treatment with tumor necrosis factor inhibitors in patients with rheumatoid arthritis with low disease activity or remission: A randomized double-blind placebo-controlled trial","volume":"75","author":"Ward","year":"2025","journal-title":"Seminars in Arthritis and Rheumatism"},{"issue":"1","key":"10.1016\/j.semarthrit.2026.153082_bib0025","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1136\/annrheumdis-2014-205726","article-title":"Full dose, reduced dose or discontinuation of etanercept in rheumatoid arthritis","volume":"75","author":"van Vollenhoven","year":"2016","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"3","key":"10.1016\/j.semarthrit.2026.153082_bib0026","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1136\/annrheumdis-2014-206149","article-title":"Maintenance of remission following 2\u2005years of standard treatment then dose reduction with abatacept in patients with early rheumatoid arthritis and poor prognosis","volume":"74","author":"Westhovens","year":"2015","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"12","key":"10.1016\/j.semarthrit.2026.153082_bib0027","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1007\/s10067-016-3413-8","article-title":"Optimizing therapy in inflammatory arthritis: prediction of relapse after tapering or stopping treatment for rheumatoid arthritis patients achieving clinical and radiological remission","volume":"35","author":"El Miedany","year":"2016","journal-title":"Clinical Rheumatology"},{"issue":"1","key":"10.1016\/j.semarthrit.2026.153082_bib0028","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1136\/annrheumdis-2014-206696","volume":"75","author":"Fautrel","year":"2016","journal-title":"Annals of the Rheumatic Diseases"},{"issue":"8","key":"10.1016\/j.semarthrit.2026.153082_bib0029","doi-asserted-by":"crossref","first-page":"1810","DOI":"10.1002\/art.39626","article-title":"Stopping tumor necrosis factor inhibitor treatment in patients with established rheumatoid arthritis in remission or with stable low disease activity: a pragmatic multicenter, open-label randomized controlled trial","volume":"68","author":"Ghiti Moghadam","year":"2016","journal-title":"Arthritis Rheumatol"},{"issue":"5","key":"10.1016\/j.semarthrit.2026.153082_bib0030","doi-asserted-by":"crossref","first-page":"651","DOI":"10.3109\/14397595.2015.1123349","article-title":"Discontinuation of etanercept after achievement of sustained remission in patients with rheumatoid arthritis who initially had moderate disease activity: results from the ENCOURAGE study, a prospective, international, multicenter randomized study","volume":"26","author":"Yamanaka","year":"2016","journal-title":"Mod Rheumatol"},{"issue":"Suppl 2","key":"10.1016\/j.semarthrit.2026.153082_bib0031","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1136\/annrheumdis-2019-eular.3055","article-title":"SAT0135 Maintaining remission in patients with established rheumatoid arthritis while tapering etanercept: an insight in the TAPERA trial","volume":"78","author":"Bertrand","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.semarthrit.2026.153082_bib0032","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1186\/s13075-021-02566-z","article-title":"Switching from TNF\u03b1 inhibitor to tacrolimus as maintenance therapy in rheumatoid arthritis after achieving low disease activity with TNF\u03b1 inhibitors and methotrexate: 24-week result from a non-randomized, prospective, active-controlled trial","volume":"23","author":"Jung","year":"2021","journal-title":"Arthritis Res Ther"},{"issue":"10","key":"10.1016\/j.semarthrit.2026.153082_bib0050","doi-asserted-by":"crossref","first-page":"1506","DOI":"10.3390\/ph18101506","article-title":"The association between serum drug concentration and a flare in rheumatoid arthritis patients tapering TNF inhibitors","volume":"18","author":"Layegh","year":"2025","journal-title":"Pharmaceuticals"},{"issue":"5","key":"10.1016\/j.semarthrit.2026.153082_bib0051","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1002\/acr2.11656","article-title":"Predicting flare in patients with rheumatoid arthritis in biologic induced remission, on tapering, and on stable therapy","volume":"6","author":"Gul","year":"2024","journal-title":"ACR Open Rheumatol"},{"issue":"8","key":"10.1016\/j.semarthrit.2026.153082_bib0052","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1038\/s41591-020-0939-8","article-title":"Distinct synovial tissue macrophage subsets regulate inflammation and remission in rheumatoid arthritis","volume":"26","author":"Alivernini","year":"2020","journal-title":"Nat Med"},{"issue":"11","key":"10.1016\/j.semarthrit.2026.153082_bib0053","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.3899\/jrheum.160193","article-title":"Subclinical synovitis assessed by ultrasound predicts flare and progressive bone erosion in rheumatoid arthritis patients with clinical remission: a systematic review and metaanalysis","volume":"43","author":"Han","year":"2016","journal-title":"J Rheumatol"},{"issue":"8","key":"10.1016\/j.semarthrit.2026.153082_bib0054","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1007\/s10067-014-2634-y","article-title":"Presence of power Doppler synovitis in rheumatoid arthritis patients with synthetic and\/or biological disease-modifying anti-rheumatic drug-induced clinical remission: experience from a Chinese cohort","volume":"33","author":"Geng","year":"2014","journal-title":"Clin Rheumatol"},{"issue":"2","key":"10.1016\/j.semarthrit.2026.153082_bib0055","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1136\/jim-2017-000558","article-title":"Biological tapering and sonographic flare in rheumatoid arthritis","volume":"66","author":"Ko","year":"2018","journal-title":"J Investig Med"},{"issue":"8","key":"10.1016\/j.semarthrit.2026.153082_bib0056","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1136\/annrheumdis-2020-217246","article-title":"Adalimumab dose tapering in patients with rheumatoid arthritis who are in long-standing clinical remission: results of the phase IV PREDICTRA study","volume":"79","author":"Emery","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.semarthrit.2026.153082_bib0057","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1136\/annrheumdis-2018-214970","article-title":"Gradual tapering TNF inhibitors versus conventional synthetic DMARDs after achieving controlled disease in patients with rheumatoid arthritis: first-year results of the randomised controlled TARA study","volume":"78","author":"van Mulligen","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"11","key":"10.1016\/j.semarthrit.2026.153082_bib0058","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1136\/ard-2023-224476","article-title":"Effect of tapered versus stable treatment with tumour necrosis factor inhibitors on disease flares in patients with rheumatoid arthritis in remission: a randomised, open label, non-inferiority trial","volume":"82","author":"Lillegraven","year":"2023","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"10.1016\/j.semarthrit.2026.153082_bib0059","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1159\/000527186","article-title":"Relative remission and low disease activity rates of tofacitinib, baricitinib, upadacitinib, and filgotinib versus methotrexate in patients with disease-modifying antirheumatic drug-naive rheumatoid arthritis","volume":"108","author":"Lee","year":"2023","journal-title":"Pharmacology"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017226001721?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017226001721?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T23:44:21Z","timestamp":1791416661000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017226001721"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":37,"alternative-id":["S0049017226001721"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2026.153082","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative efficacy and safety of disease-modifying antirheumatic drugs tapering strategies in sustained-remission rheumatoid arthritis: Systematic review and network meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2026.153082","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"153082"}}